POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.6 CHF | -1.21% |
|
-0.46% | +86.07% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
| Sales 2024 * | 349M 380M 346M | Sales 2025 * | 411M 447M 408M | Capitalization | 1.1B 1.19B 1.09B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -13.05M -11.89M | Net income 2025 * | 14M 15.23M 13.88M | EV / Sales 2024 * | 3.35 x |
| Net Debt 2024 * | 73.61M 80.05M 72.95M | Net Debt 2025 * | 116M 126M 115M | EV / Sales 2025 * | 2.95 x |
| P/E ratio 2024 * |
-127
x | P/E ratio 2025 * |
64.8
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.13% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | +2.50% | ||
| 1 week | +3.21% | ||
| Current month | +11.55% | ||
| 1 month | +11.18% | ||
| 3 months | +103.74% | ||
| 6 months | +84.30% | ||
| Current year | +92.92% |
1 week
31.35
34.00
1 month
28.4534.60
Current year
14.1134.60
1 year
14.1134.60
3 years
14.11147.40
5 years
14.11147.40
10 years
14.11147.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 23-04-11 | |
| Chief Tech/Sci/R&D Officer | 52 | 11-12-31 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 20-12-31 | |
Peter Wilden
CHM | Chairman | 67 | 21-03-31 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +4.20% | - | |
| 0.00% | 25 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 32.6 | -1.21% | 14 098 |
| 24-05-27 | 33 | +3.29% | 11,743 |
| 24-05-24 | 31.95 | -1.39% | 17,100 |
| 24-05-23 | 32.4 | -1.37% | 29,721 |
| 24-05-22 | 32.85 | +0.31% | 33,413 |
Delayed Quote Swiss Exchange, May 28, 2024 at 04:07 am EDT
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
33.26
EUR
Average target price
25.12
EUR
Spread / Average Target
-24.46%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +92.92% | 1.19B | |
| +38.51% | 727B | |
| +32.09% | 594B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +14.17% | 243B | |
| +8.08% | 205B | |
| -5.48% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- PPGN Stock
